News

Results from the Phase 3 OPTIMIZE-1 trial of OCS-01, a once-daily, preservative-free corticosteroid eye drop, were presented at the 2024 ASCRS Annual Meeting.

While no adverse events have been reported for any of the copycat products, the agency has received complaints of quality concerns, eye irritation, pain and infection.

Congress is being called upon by the Food and Drug Administration to bestow new powers upon the agency to mandate recalls and force eyedrop manufacturers to be subjected to inspections prior to th...

The eye drops market has been hit yet again with potentially contaminated eye drops that can cause serious eye infections or even blindness.

Since the beginning of 2023, several eye drops and lubricants have been recalled by the Food and Drug Administration.

The Food and Drug Administration (FDA) has sent letters to two manufacturers regarding their unlawful marketing of amniotic fluid eyedrops.

Topical, non-invasive treatments may soon be available to people over the age of 40 who need reading glasses.